Methyl bromoacetate → HCID 13457778, 화합물

HRID 463516노트

반응식

HRID 463516 반응식
[CH2:1]([O:8][C:9]([CH:11]1[CH2:17][CH2:16][CH2:15][CH2:14][NH:13][CH2:12]1)=[O:10])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.Br[CH2:19][C:20]([O:22][CH3:23])=[O:21]>C1C=CC=CC=1.[Ag]=O>[CH3:23][O:22][C:20]([CH2:19][N:13]1[CH2:14][CH2:15][CH2:16][CH2:17][CH:11]([C:9]([O:8][CH2:1][C:2]2[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=2)=[O:10])[CH2:12]1)=[O:21]

참가 물질

5

반응물 2

HCID 60984Methyl bromoacetateHCID 13457777Benzyl azepane-3-carboxylate

생성물 1

HCID 13457778HCID 13457778, 화합물

시약·촉매·용매 2

HCID 92152Silver(II) oxide촉매HCID 241Benzene용매

실험 절차

To a solution of 1.46 g 3-benzyloxycarbonylperhydroazepine and 1.06 g methvl bromoacetate in 30 ml benzene add 1.06 g silver oxide. Stir the reaction in the dark for 24 hr., filter and concentrate the filtrate in vacuo. Dissolve the residue in HCl (pH 1.5) and wash the solution with ether. Make the aqueous phase to pH 12 and extract with ethyl acetate. Dry and concentrate the extracts to obtain 1-methoxycarbonylmethyl-3-benzyloxycarbonylperhydroazepine. NMR (CDCl3, TMS)-δ 1.8 ;(m, 6H); δ 2.8 (m, 2H); δ 3.1 (d, 2H); δ 3.45 (s, 2H); δ 3.65 (s, 3H); δ 5.15 (s, 2H); δ 7.3 (s, 5H).

후처리

  1. customthe reaction in the dark for 24 hr
  2. filtration, filter
  3. concentrationconcentrate the filtrate in vacuo
  4. dissolutionDissolve the residue in HCl (pH 1.5)
  5. washwash the solution with ether
  6. extractionextract with ethyl acetate
  7. customDry
  8. concentrationconcentrate the extracts

출처 및 근거

ORD 기록
ord-a99cca3ed5b945f79e137ad8390b60e8
출처 데이터셋
uspto-grants-1985_05
특허 번호
US04520021

반응 노트

불러오는 중…